SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424432.
  • 2
    Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504510.
  • 3
    Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11: 716732.
  • 4
    Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 17141722.
  • 5
    Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, et al. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. J Viral Hepat 2005; 12: 154159.
  • 6
    Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49: 860863.
  • 7
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 6: 107113.
  • 8
    Chan HL, Chui AK, Lau WY, Chan FK, Hui AY, Rao AR et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004; 18: 295300.
  • 9
    Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402409.
  • 10
    Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532538.
  • 11
    Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for pre- and post-liver transplantation patients with lamivudine-resistant hepatitis B. Liver Transpl 2007; 13: 349360.
  • 12
    Peters MG, Hann HH, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 13
    Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283290.
  • 14
    Lampertico P, Marzano A, Levrero M, Santantonio T, Andreone P, Brunetto M, et al. A multicenter Italian study of rescue adefovir dipdvoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients. Hepatology 2005; 42( Suppl 1): 591.
  • 15
    Snow A, Thibault V, Qi X, Zhu Y, Westland C, Arterburn S, et al. Combination of adefovir dipivoxil (ADV) and lamivudine (LAM) prevented emergence of ADV resistance mutations in chronic hepatitis B (CHB) patients with LAM-resistant HBV. Gastroenterology 2005; 128( Suppl 2): A745.
  • 16
    Durantel S, Werle B, Durantel D, Pichoud C, Currie G, Xiong S, et al. Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B. Hepatology 2004; 40( Suppl 4): 654A.
  • 17
    Valdes A, Buti M, Jardi R, Rodriguez-Frias F, Schaper M, Esteban R, et al. Non-response and resistance to adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. J Hepatol 2006; 44( Suppl 2): 191.
  • 18
    Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 13851391.
  • 19
    Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 8695.
  • 20
    Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 13911398.
  • 21
    Peters MG, Anderson J, Lynch P, Jacobson J, Sherman K, Alston Smith B, et al. Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are co-infected with HIV: results of ACTG A5127. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005:Abstract 124. Foundation for Retrovirology and Human Health, in scientific collaboration with the National Institute of Allergy and Infectious Diseases and Centers for Disease Control and Prevention (http://www.retroconference.org/2005/home.htm).
  • 22
    Schildgen O, Hartmann H, Gerlich WH. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol 2006; 41: 245246.
  • 23
    van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 14211425.
  • 24
    van Bommel F, Berg T. Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology 2005; 42: 239240.
  • 25
    van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318325.
  • 26
    Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 34983507.
  • 27
    Sherman M, Martin P, Lee WM, Yurdaydin C, Sollano J, Vaughan J, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). Gastroenterology 2006; 130( Suppl 2): A765.
  • 28
    Colonno RJ, Rose RE, Levine SM, Pokornowski K, Plym M, Yu CF, et al. Entecavir (ETV) resistance is not observed in nucleoside-naive subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection. J Hepatol 2005; 42( Suppl 2): 173.
  • 29
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 30
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.